The Global Health Body Issues Alert Over Severe Shortage of Weight-Loss Jabs
Less than 10% of individuals that would benefit from obesity jabs like Wegovy can access them, warns the WHO as it releases its first guidance on the drugs.
Given in excess of 1,000,000,000 people worldwide currently living with obesity, it is advocating for broader and more equitable access to these injectable treatments.
Per forecasts, in excess of 2,000,000,000 will be living with obesity by 2030 without intervention.
"Our new guidance affirms that excess weight is a lifelong illness that can be treated with comprehensive and continuous support," said the agency's head Tedros Adhanom Ghebreyesus.
High costs, insufficient output, and supply-chain constraints are significant hurdles to broad access to the injections that can help people shift considerable body mass, says the organization.
Weight-Loss Drug Shortage
Despite the present best projected case, the supply of such drugs would only suffice for approximately 100 million people – fewer than 10% of the global need, according to the WHO.
The guideline calls on governments and firms to increase availability, through measures including patent sharing.
Exclusive production rights on a key compound – the primary ingredient of Novo Nordisk's Wegovy – is scheduled to end in multiple nations in 2026.
The Way Weight-Loss Drugs Operate
The injections imitate a body's own hormone to slow digestion, reduce hunger and enhance feelings of fullness so individuals consume fewer calories.
Individuals typically see weight reduction in the initial weeks of beginning the once-weekly jabs.
Evidence indicates people may see weight return within a year of stopping the treatment, as their typical food cravings return.
To be carrying excess weight elevates your chance for developing diseases, including diabetes, heart disease, stroke, and specific malignancies.
Excess weight affects people in all nations and was associated with millions of fatalities worldwide in 2024, according to the WHO.
